Goldman Sachs’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Goldman Sachs’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,549	Closed	-$7.79K	–	6286
2023 Q1	$7.79K	Sell	30,549 -2,330	-7%	-$2.1K	﹤0.01%	5762
2022 Q4	$38.8K	Buy	+32,879	New	+$69.1K	﹤0.01%	5628
2022 Q2	–	Sell	-15,620	Closed	-$79K	–	6857
2022 Q1	$79K	Buy	+15,620	New	+$71K	﹤0.01%	6173
2021 Q3	–	Sell	-130,526	Closed	-$1.29M	–	6616
2021 Q2	$1.29M	Buy	130,526 +90,986	+230%	+$892K	﹤0.01%	4568
2021 Q1	$382K	Buy	+39,540	New	+$382K	﹤0.01%	5296

Goldman Sachs's PEAR Position: Q2 2023 in Review

Goldman Sachs sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 30,549 shares — an estimated $7.79K sold.

Goldman Sachs first reported a position in PEAR in Q1 2021 and held it in 5 quarters. The position peaked at $1.29M in Q2 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Goldman Sachs reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 30,549 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $7.79K.
Goldman Sachs first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2021 and held it in 5 quarters.
Goldman Sachs's Pear Therapeutics, Inc. Class A Common Stock position peaked at $1.29M in Q2 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.